TRANSCAN-2’s fourth joint transnational call: Translational research on rare cancers
” The decisions concerning the focus of the present call are strongly motivated by the challenges related to research and treatment in rare cancers, which are intimately tightened to the low incidence of any single clinical-pathological entity currently listed among these cancers. Proposals will have to cover a minimum of one of the specific aims reported below, and within the aim/s of choice, the applicants will have to address at least one of the topics listed as bullet points. Proposals addressing one single aim and one single bullet point within the chosen aim will be allowed:
Aim 1: Design and conduct of translational research studies exploiting/combining resources from current clinical trials, bio-repositories and epidemiology-type resources.
Aim 2: Development and exploitation of translational research platforms (e.g., patient derived xenograft models/organoids/tissue collections) to study drug responses/resistance and toxicity, and perform drug screens or repurpose approved anticancer drugs.
Aim 3: Implementation of precision biomarkers for better stratification of the clinical cohorts.”
For more information on the call, please visit TRANSCAN’s website.
Similarly to the JTC 2016, the ECaDE group co-led by EATRIS will provide support to applicants free of charge. For more information, please visit our dedicated page.